

# CRISPR/Cas9 gene editing technology and its application to the coronavirus disease (COVID-19), a review


Saeid CHEKANI-AZAR<sup>1</sup>, Ehsan GHARIB MOMBENI<sup>2</sup>, Mastewal BIRHAN<sup>3\*</sup> and Mahshad YOUSEFI<sup>4</sup>

<sup>1</sup>PhD, Faculty of Veterinary Medicine, Animal Physiology, Atatürk University, Turkey

<sup>2</sup>Department of Pathobiology, Shahid Chamran University of Ahvaz, Iran

<sup>3</sup>College of Veterinary Medicine and Animal Science, Department of Veterinary Paraclinical Studies, University of Gondar, Ethiopia

<sup>4</sup>MD, Hamadan University of Medical Sciences, Hamadan, Iran

\*Corresponding author's Email: [maste675@gmail.com](mailto:maste675@gmail.com);  ORCID: 0000-0002-0984-5582

## ABSTRACT

**Introduction.** Clustered-Regularly Interspaced Short Palindromic Repeats (CRISPR), and CRISPR associated (Cas) protein (CRISPR/Cas) structures were first identified in *E. coli* in 1987 and guard prokaryotic cells from any invading pathogens, harmful events and plasmids by recognizing and cutting foreign nucleic acid sequences that contain short palindromic repeats spacer sequences. Several genome editing approaches have been developed based on these mechanisms; the most recent is known as CRISPR/Cas. Before the CRISPR technique was revealed in 2012, editing the genomes of plants and animals took many years and cost hundreds of thousands of dollars. Thus, CRISPR/Cas has attracted significant interest in the scientific community, especially for disease diagnosis and treatment, as it is quicker, less expensive and more precise than other genome editing approaches. The evidence from gene mutations in specific patients generated using CRISPR/Cas can assist in the prediction of the optimal treatment schedule for individual patients and for innovation purposes in other researches like replication in cell culture of coronaviruses like severe acute respiratory syndrome coronavirus-2 (SARS-CoV2 or COVID-19). However, in numerous situations, the effects of the furthest significant driver mutations are not yet understood and interpretation of the optimal treatment is impossible. CRISPR/Cas classifications feature highly sensitive and selective tools for the detection of various target genes. When we see the next steps of genomic research, it is obvious that genome-wide association studies are relatively new way to identify the genes involved in human disease. Furthermore, CRISPR/Cas provides a tool to manipulate non-coding regions and will thus accelerate examination of these poorly characterized regions of the genome and play a vital role in the progress of whole genome libraries. **Aim.** We aimed to review the history of CRISPR/Cas, the mechanisms of CRISPR techniques, its current status as a tool for studying both natural mutations and genomic manipulations, and explore how CRISPR/Cas may improve the treatment of diseases.

## Review Article

PII: S225199392000001-10

Rec. 22 December 2019

Rev. 15 January 2020

Pub. 25 January 2020

## Keywords

CRISPR/Cas9,

DNA-targeting,

Palindromic,

Plasmids,

Genome sequencing,

SARS-CoV2,

COVID-19

## INTRODUCTION

Clustered regularly interspersed short palindromic repeats (CRISPR) were first discovered in *Escherichia coli* in 1987 and later found in other bacteria species. The role of these repeat sequences remained unclear until, in 2005, several researchers described the similarities of the sequences' DNA, leading to the hypothesis that the sequences are part of adaptive immune system in bacteria (CRISPR/Cas9 for cancer research and therapy).

As you know, CRISPR is also refers to an adaptive immune response in bacteria and archaea that is cast-off to target and cut down viral DNA by using endonuclease in specific ways. By reengineering this immune response to target parts of genetic material, scientists could make extremely precise genetic alterations tailored to the type of cell. This is the basis of CRISPR therapeutic and diagnostic platforms [1].

CRISPR and CRISPR-associated proteins characterize the immune system of archaea and bacteria, and deliver protection against invasive nucleic acids, DNA, or RNA from phages, plasmids, and other exogenous DNA elements. At this time, two different classes, six types, and 21 subtypes of CRISPR–Cas systems have been identified [2]. The length of the repeat sequences varies between 25 and 40 nt, whereas the length of the spacer sequences varies between 21 and 71 nt [3].

For the success of these, innumerable methods have been fashioned for targeted gene editing in cell and animal models. These include Zinc-Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs). But, Clustered-Regularly Interspaced Short Palindromic Repeats (CRISPR), and CRISPR Associated (Cas) protein (CRISPR/Cas) is a rapid, simple, and often extremely efficient gene editing method [4]. That is why? It is a powerful method for making changes and simple to manipulate the genome of many organisms [5]. From these scientific truth, we can understand the advantage of genome editing tools made possible to modify a genomic DNA in a targeted fashion by applying of CRISPR/Cas [6].

Recent developments in CRISPR/Cas gene editing have made it possible to introduce precise changes into a wide variety of genomes, including those of dsDNA viruses; in addition to this, it is pursuing relies on the co-expression of a prokaryotic Cas nuclease and an associated guide RNA (gRNA) sequence. Because, once gRNA-targeted Cas, it creates a double-stranded break (DSB) in the genome, by making of two main repair processes compete to repair the damage, leading to with some modifications of from the original sequence [7].

The study of gene function in the recent decades has trusted on the generation of systemic and conditional gene knockouts to disrupt gene expression especially in coronaviruses. For example, *de Wilde et al.* [8] investigated the CypA-dependence in the replication of three related nidoviruses in the same cell line (Huh7), in which CypA expression was knocked-out using CRISPR/Cas9 gene editing technology (Huh7-CypAKO cells). Therefore, even if successful studies and some innovation ideas and solution were done, but, it has been challenging to knockout a gene in specific cell types in the brain. The final target and goals of CRISPR was to revolutionize the treatment of hereditary diseases based therapeutics. Finally, the aim of this systematic review paper is to summarize the application of CRISPR/Cas and its overall immune signal transduction and also discussing gene editing technology against novel diseases like coronavirus (COVID-19).

## Current status and significance of CRISPR/CAS and immune cells

### Types of CRISPR/Cas systems

CRISPR/Cas systems have been categorized in details such as class 1 which utilizes multi-protein effector complexes and class 2 which utilizes single-protein effectors. Class 1 is further divided into different types I, III, and IV, while class 2 includes types II, V, and VI. It can also be divided into 19 different subtypes and it is likely to continue to expand as new CRISPR/Cas systems are identified. The greatest corporate Cas protein used for functional broadcast is a type II single-protein effector derived from *Streptococcus pyogenes* (SpCas9). It is a type of guide RNA to succor in successfully cleaving the target gene [9].

This choice stems from the fact that types I and III are composed of a number of Cas proteins, although the Cas9 protein is the only protein constituent of type II CRISPR/Cas systems [10]. One of the difficulties in classifying and applying for the success is designing and construction of novel CRISPR/Cas systems with the researcher effort to demarcate targeting sequences in a simplified manner [11]. Type II system is composed of trans-activating crRNA (tracrRNA). CRISPR loci are prepared of "repeat-spacer" array and adjacent to small clusters of Cas genes including Cas9 endonuclease [12]. From this perspective, Cas proteins are of great necessity for the functioning of CRISPR/Cas immune system and are considered as indicators of the system's activity [13].

### CRISPR in human pluripotent stem cells


Human civilization has always faced two basic challenges: That are disease and hunger. Efforts to prevent or treat disease and accomplish food security endure. Despite of the progress made food insecurity and many. Diseases and pests persist; these problems have proved difficult to solve using available technologies. Nevertheless, hopes are high for solutions to many of these challenges with the advent of CRISPR technology [14]. There are different human cells those are, immortalized MRC5-hTERT fibroblasts were cultured in Dulbecco's modified Eagle medium, supplemented with fetal bovine serum (10%), 1% penicillin-streptomycin and 4.5 g/L glucose, [7].

### Overview of CRISPR-Cas-mediated genome editing

Engineered nucleases, such as ZFN, TALEN, and Cas9, can induce DNA double-strand breaks (DSBs) at specific genomic loci, which are subsequently repaired by one of at least two endogenous cellular DNA repair pathways: non-homologous end joining (NHEJ) and homology-directed repair (HDR) [16]. Over the past two decades, the discovery of programmable DNA binding proteins (ZFs, Zinc fingers, and transcription activator-

like effectors [TALEs]) has paved the way for the development of genome editing tools. Compared with ZFs, which contain repeated Cys2-His2 (C2H2), DNA binding domain (DBD) adapted from a family of eukaryotic transcription factors (TFs) [17].

The CRISPR-Cas9 genome-editing technology is derived from the adaptive immune response in prokaryotes. This method has several advantages over conventional genome-editing technologies, including: a) simplicity in target designing, b) regulation, and c) the ability to target multiple genes. CRISPR consists of two major components: sgRNA and Cas protein. The sgRNA consists of a sequence, also called as scaffold. sgRNA includes a Cas enzyme binding site and a spacer sequence, called the target sequence, which is specific to the gene of interest. The spacer sequence contains ~20 nucleotides and is followed by protospacer adjacent motif (PAM), a 2–6-base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease in the CRISPR. PAM sequences vary based upon the type of Cas9 enzyme [18].



**Figure 1.** Promoting safety in genome editing [15].

### Editing efficiency

There are a number of changes and factors that contribute for the difficulty of genome editing. The second major challenge in the genome editing is efficiency. The therapeutic efficacy of genome editing will be enhanced by improving the editing rates. For CRISPR-Cas, the activity of double-strand break (DSB) restoration pathways plays an important regulatory role in its editing rates.

Due to the different endogenous cellular DNA repair mechanisms mediated by non-homologous end-joining (NHEJ) and homology-directed repair (HDR), there are definitely more editing efficiency differences in both different cell types and also cellular states. HDR is differently operates during the S/G2 phase while NHEJ is active during the whole cell cycle, thus, it is generally more efficient for generating indels to knockout carcinogenic genes than HDR. The efficiency of HDR, as precise gene adjustment, is relatively lethargic depending on both homology arm length and DNA template type. HDR templates are typically single-stranded oligonucleotides or plasmids containing alleles and delivery of HDR templates has been accomplished with viral or non-viral vectors [19].

### CRISPR/Cas9 toolsets

There are a number of online CRISPR tools and resource available, provided by both academic and commercial institutions, with a list and its application of the most widely used resources provided in Table 1. The function of these CRISPR resources is primarily to identify and recognized gRNAs, and provide the essential information required to select gRNAs for experimental applications. While some of the tools may be able to “mention” gRNAs for specific purposes. However for most applications, these CRISPR tools are just one component of the overall design process that starts with the identification of target locations [20].

**Table 1.** List of common CRISPR resources [20].

Name	URL
Addgene	<a href="http://www.addgene.org/crispr/">http://www.addgene.org/crispr/</a>
Benchling	<a href="https://benchling.com/crispr">https://benchling.com/crispr</a>
BreakingCas	<a href="http://bioinfogpp.cnb.csic.es/tools/breakingcas/">http://bioinfogpp.cnb.csic.es/tools/breakingcas/</a>
Broad Institute GPP	<a href="https://portals.broadinstitute.org/gpp/public/">https://portals.broadinstitute.org/gpp/public/</a>
CHOPCHOP	<a href="http://chopchop.cbu.uib.no/">http://chopchop.cbu.uib.no/</a>
CRISPOR	<a href="http://crispor.net/">http://crispor.net/</a>
CrisFlash	<a href="https://github.com/crisflash/crisflash">https://github.com/crisflash/crisflash</a>
Deskgen	<a href="https://www.deskgen.com">https://www.deskgen.com</a>
E-CRISP	<a href="http://www.e-crisp.org/E-CRISP/">http://www.e-crisp.org/E-CRISP/</a>
Horizon Discovery	<a href="https://dharmacon.horizondiscovery.com/gene-editing/crispr-cas9/crispr-design-tool/">https://dharmacon.horizondiscovery.com/gene-editing/crispr-cas9/crispr-design-tool/</a>
IDT	<a href="https://sg.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM">https://sg.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM</a>
Microsoft Research CRISPR	<a href="https://crispr.ml">https://crispr.ml</a>
RGEN Tools	<a href="http://www.rgenome.net/">http://www.rgenome.net/</a>
Synthego	<a href="http://design.synthego.com">http://design.synthego.com</a>
WTSI Genome Editing (WGE)	<a href="https://www.sanger.ac.uk/htgt/wge/">https://www.sanger.ac.uk/htgt/wge/</a>

WTSI: Wellcome Trust Sanger Institute, RGEN: RNA-Guided Endonucleases, GPP: Green Public Procurement,

### CRISPR applications and design

For the applications systems of all CRISPR/Cas is depend on the gRNA's ability to recognize specific target sequence, even though not all applications are dependent on the cleavage activity of the Cas-endonuclease. Because of both knock-in (KI) and knock-out (KO) solicitations are related to the formation of a DSB to insert DNA or either delete [20, 21]. Designing needs about the basic principles of CRISPR that involved to identifying a suitable target region or regions, tracked by the choices of suitable gRNAs based on positioning the target region: off-target and on-target scoring. This is very important for the applies of both targeted design and large-scale design approaches, even though the methods used for selecting and targeting gRNAs can be exact different between these approaches [20].

There are invaluable information for systematic analyses of the genes which can be achieved by parameters like molecular characterization, mechanics behind biological processes, and screening of therapies and responses to drugs [22]. When we see for example like cancer: it is a genetic disease stemming from cumulative genetic/epigenetic aberrations, it is rational for us to envisage that modifying the oncogenic genome abnormalities through CRISPR/Cas might characterize a promising therapeutic strategy against cancer [19]. Introducing only a single DSB to stimulate the DNA-repair mechanisms can be sufficient, but even introducing more than one DSB for large deletions or insertions may be necessary. In the lack of a repair template, NHEJ pathway may introduce small idles within a coding sequence, which can disrupts protein translation by a frame shift and thus knockout a gene. An ideas suitable for DNA repair template is on condition that, the same double-stranded break (DSB) may be repaired by homology-directed repair (HDR), leading to the insertion or knock-in of any exogenous DNA included within the template. In contrast, CRISPR repression and activation (CRISPRa/i) uses a catalytically dead or inactivated Cas-endonuclease to target transcriptional repressor complexes or activator to a specific site within the promoter region [20].

Today, the application of the CRISPR/Cas9 method has expanded into a variety of areas, including agriculture, husbandry, disease patterns and targeted therapies. This section emphasizes the therapeutic aspects for diseases with a genetic basis, especially monogenic disorders. In the *ex vivo* approach, the targeted cell population is removed from the patient's body, and the designed nucleases are used to induce the desired changes and then returned to the patient by grafting. Avoiding issues such as transplant rejection and immune responses are important benefits of this method. Using *in vivo* gene therapy, the genomic modifying factors, such as programmatic nucleases and patterns, are put directly into the patient [23].

In the case of Cas9; it is used to change endogenous genes which previously were problematic to be genetically manipulated, resulting in a more efficient and faster production of transgenic models. Those transgenic models that can be produced simply by injecting fertilized zygotes with customized Cas9 and transcribed single guide RNA for the manipulation of alleles and accomplish desired alterations in mammalians. Cas9 is also used in cellular models to study for the treatment and diagnosis of polygenic diseases such as diabetes and autism due to multiplexing properties [24].



## CRISPR/Cas9 gene editing technology applications against diseases like COVID-19

CRISPR/Cas biotechnology is now expansively and broadly applied across numerous disciplines, including basic sciences, food/crop development, fuel generation, drug development, human genome engineering and gene editing technology against novel diseases like coronavirus (COVID-19 or SARS-CoV2) [8, 14, 19, 22, 25, 26].

The Nidovirales that are consisted of the ronivirus, mesonivirus, arterivirus, and coronavirus families have minor or major economic and societal effects. In 2002–2003, the highly pathogenic outbreaks (ongoing), human coronaviruses (HCoVs), severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) occurred in zoonotic and transmitted to the human population, with alarming mortality. SARS-CoV outbreaks led to more than 8000 confirmed cases within a few months, (mortality rate: ~ 10%) [27] and for the MERS-CoV resulted in over 2000 human cases (~ 35% mortality rate) (<http://www.who.int/emergencies/mers-cov/en/>) [28]. But in December 2019, another pathogenic HCoV, 2019 named novel coronavirus (2019-nCoV, COVID-19 or SARS-CoV2), was recognized in Wuhan, China [29, 30], and has caused serious mortality rate of ~ 35% (<https://www.worldometers.info/coronavirus/>). In most patients, COVID-19 infection is associated with a cytokine storm [27, 28, 30-33]. In recovered cases, the excessive immune responses lead to long-term lung damage and fibrosis, causing functional disability and reduced quality of life [34, 35]. There is no specific anti-viral treatment, and designing effective antiviral drugs against COVID-19 will take several years to develop and evaluate and also a range of existing host-directed safe therapies [36-38] could potentially be repurposed to treat COVID-19 infection. Hence, an urgent funding and scientific investments into advancing novel therapeutic interventions for coronavirus infections, is required.

Therefore, the lack of proper strategies to control nidovirus-induced disease, increase the importance of knowledge of these viruses' replications and also their interactions with the host cell and specially role of CRISPR-Cas gene editing technology against these viruses. Nidoviruses are +RNA viruses with different genomes (arteriviruses with 13 to 16 kb, and coronaviruses with 26–34 kb) [39, 40], with a complex genome translation for producing the nsps (polyprotein precursors of the nonstructural proteins) as well as a nested set of subgenomic (sg) mRNAs to express the structural proteins [41, 42]. Nidoviral nsps, probably with various host factors, assemble into replication and transcription complexes (RTCs) that drive viral RNA synthesis [43-46]. These RTCs are probably associated with a virus-induced network of endoplasmic reticulum-derived membrane (ERDM) structures, including many double-membrane vesicles [43, 47-49].

Nidovirus replication depends on membrane trafficking, cellular proteins and membranes, and host signaling pathways or host cell factors and processes [50-52]. The cyclophilin (Cyp) protein family members have been implicated in nidovirus replication. The Cyps family of peptidyl-prolyl isomerases (PPIases), act as chaperones to facilitate protein folding, trafficking and immune cell activation [53, 54]. Cyps family that are ubiquitous and abundant cytosolic proteins, are especially expressed CypA, an important factor that implicated in the replication of various RNA viruses. CypA have also specific roles in various viruses like human hepatitis C virus (HCV) and immunodeficiency virus-1 (HIV-1) infections. It assists HCV polyprotein processing, interacts with HCV NS5A for remodelling of cellular membranes into HCV replication organelles, and stabilizes HIV-1 capsids to promote nuclear import of the HIV-1 genome [55].

Studies with general Cyp inhibitors such as cyclosporine A (CsA) showed that, cyclophilins were initially implicated as host factors in nidovirus replication. In cell culture, the replication of a variety of arteriviruses and coronaviruses was found to be strongly inhibited by lowmicromolar concentrations of CsA and the non-immunosuppressive CsA analogs Alisporivir (ALV) and NIM-811 [56-63]. And then nidovirus replication can depend specifically on CypA and/or CypB.

The replication in cell culture of the alphacoronaviruses feline coronavirus [64], the arterivirus equine arteritis virus (EAV) [65]; and human coronavirus (HCoV)-NL63 [56], and HCoV-229E [63] was reported to be affected by CypA knockout or knockdown. Finally, it seems that the normally cytosolic CypA was found to co-sediment with membrane structures containing EAV RTCs, have a direct association with the arteriviral RNA-synthesizing machinery [65].

All the studies are depends on the nidoviruses types and cell lines, CypA expression levels, and readouts to measure viral replication efficiency. *de Wilde et al.* [8] investigated the CypA-dependence of the replication of three related nidoviruses in the same cell line (Huh7), in which CypA expression was knocked-out using CRISPR/Cas9 gene editing technology (Huh7-CypAKO cells). Using different cell lines, the replication of the arterivirus EAV [65] and the alphacoronavirus HCoV-229E [63], was previously concluded to depend on CypA. And the CypA dependence of betacoronaviruses like MERS-CoV has been documented for a first time with *de Wilde et al.* [8]. They reported that infection of Huh7-CypAKO cells with MERS-CoV revealed that its replication

was only modestly affected by the absence of CypA, as opposed to equine arteritis virus which was strongly inhibited. While they stated that, HCoV-229E replication was not affected at all in the Huh7-CypAKO cells. They thus revealed major differences in CypA dependence of the arterivirus EAV in compared to other coronaviruses. There is a need to more evaluation of the CypA role in the replication of members of the latter virus family.

### **The capacity of CRISPR diagnostics**

Diagnostic uses of CRISPR technologies help immense advantages in clinical effectiveness. A vast numbers of researchers have used CRISPR-based editing and diagnosis to correct the genetic basis of many diseases in isolated from the cells of animal models. The first groundswell of clinical trials using CRISPR enzymes to treat inherited disorders in humans involves eradicating a patient's cells, editing *ex vivo*, and rein fusing the corrected cells. Such *ex vivo* genome editing is currently the most technically feasible approach, and has the potential to treat devastating blood disorders like sickle cell disease and  $\beta$ -thalassemia. The *ex vivo* strategy also underlies cancer immunotherapies [66].

The role and function of CRISPR/Cas in gene editing in applications as diverse as fetal medicine, biodefense, and synthetic food makes for a stream of high-profile news. In 2018, several articles were published on the use of CRISPR in diagnostic tests for early-stage cancer detection or for infectious diseases. Further, it was seen as the most important innovation used to develop a rapid CRISPR-based assay for TB detection [25].

### **CRISPR ethics**

Ethical decisions, particularly in biomedicine, are empirically informed and involve evaluating potential risk-benefit ratios, with the attempt of maximizing benefits while minimizing risk. To navigate ethical decision making, it is critical to consider the range of possible consequences, the probabilities of each instantiating, and the possible rationalizations driving results. The ethical concerns about CRISPR genome engineering technology are largely due to at least three important explanations. These include the possibilities of limited on-target editing efficiency [67].

CRISPR/Cas9 is inexpensive, efficient and exact method to edit genes at the level of individual nucleotides, and also help to explore or explain many scientific questions. Moreover, this gene editing technology provides new potential treatments for many human diseases like novel coronavirus (COVID-19). In addition, the use of CRISPR/Cas9 gene editing technologies along with stem cells (i.e. induced pluripotent stem cells), can help to generate gametes for reproductive purposes or correct errors in their genome, and can also minimize the need for oocyte donation [68].

In 2017, the US National Academies of Sciences, Engineering, and Medicine Committee on Human Gene Editing published reviews of scientific, legal or ethical concerns about the amazing progress of gene engineering technology. The astonishing report, was that heritable genome editing help to modification of the germ line with the aim of generating a new human being who could therefore transfer the genomic change to future generations-hold be impermissible now but eventually could be justified for certain medical indications. Currently, create, destroy, or modification of human embryos to include heritable genetic changes for research purposes, is unlawful for U.S. federal funds. The NASEM is still implies that if safety risks guaranteed, clinical trials conceivable would commence [69].

## **CONCLUSIONS AND RECOMMENDATIONS**

Form these systems review; we can appreciate the most important components of CRISPR RNAs (crRNAs) and Cas effector proteins. CRISPR will be a very important and crucial study area for disease diagnosis and treatment in the future, with the best potential for research in the scientific community. Beside this, it will be important for correcting the mutations and hereditary diseases concerning immune cells and their system disturbances; it will be important even for immunological tolerance to correct wrongly activated immune cells that fail to identify self and non-self, leading to cancerous disturbances of immune balance. It is very crucial in facilitating the etiology of diseases and checking their causative agents. From its adaption, it has revolutionized molecular biology and genetics in general. In combination with parallel developments of the necessary supportive techniques, modern biotechnology has led to useful genetic modifications of micro-organisms, plants and animals it has generated, inter alia, various new therapeutics and diagnostics. Owing to such advancements, we can study and work with this environment in an easier manner. CRISPR gene editing and



16. Nishiyama, J., *Genome editing in the mammalian brain using the CRISPR–Cas system*. *Neuroscience research*, 2019. 141: p. 4-12. DOI: <https://doi.org/10.1016/j.neures.2018.07.003>
17. Rahman, S., et al. *CRISPR/Cas: An intriguing genomic editing tool with prospects in treating neurodegenerative diseases*. in *Seminars in cell & developmental biology*. 2019. Elsevier. 96: P. 22-31. DOI: <https://doi.org/10.1016/j.semcdb.2019.05.014>
18. Kaushik, I., S. Ramachandran, and S.K. Srivastava. *CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment*. in *Seminars in cell & developmental biology*. Elsevier. 2019; 96:4-12. DOI: <https://doi.org/10.1016/j.semcdb.2019.04.018>.
19. Chen, M., et al., *CRISPR-Cas9 for cancer therapy: Opportunities and challenges*. *Cancer letters*, 2019. 447: p. 48-55. DOI: <https://doi.org/10.3390/biomedicines6040105>
20. Thomas, M., D. Parry-Smith, and V. Iyer, *Best practice for CRISPR design using current tools and resources*. *Methods*, 2019; 164–165(15 July): Pages 3-17. DOI: <https://doi.org/10.1016/j.ymeth.2019.05.019>
21. Fu, B.X.H., et al., *Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9*. *Nature microbiology*, 2019. 4(5): p. 888-897. DOI: <https://doi.org/10.1038/s41564-019-0382-0>
22. Shalem, O., et al., *Genome-scale CRISPR-Cas9 knockout screening in human cells*. *Science*, 2014. 343(6166): p. 84-87. DOI: <https://doi.org/10.1126/science.1247005>
23. Rezaei, H., et al., *Harnessing CRISPR/Cas9 technology in cardiovascular disease*. *Trends in cardiovascular medicine*, 2019; 30(2): p. 93-101. DOI: <https://doi.org/10.1016/j.tcm.2019.03.005>
24. Wang, W., et al. *The advances in CRISPR technology and 3D genome*. in *Seminars in cell & developmental biology*. 2018. Elsevier. DOI: <https://doi.org/10.1016/j.semcdb.2018.07.009>
25. Ai, J.-W., et al., *CRISPR-based rapid and ultra-sensitive diagnostic test for Mycobacterium tuberculosis*. *Emerging microbes & infections*, 2019. 8(1): p. 1361-1369. DOI: <https://doi.org/10.1080/22221751.2019.1664939>.
26. Strich, J.R. and D.S. Chertow, *CRISPR-Cas biology and its application to infectious diseases*. *Journal of Clinical Microbiology*, 2019. 57(4): p. e01307-18. DOI: <https://doi.org/doi.org/10.1128/JCM.01307-18>.
27. Hui, D.S. and A. Zumla, *Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features*. *Infectious Disease Clinics*, 2019. 33(4): p. 869-889. DOI: <https://doi.org/10.1016/j.idc.2019.07.001>
28. Azhar, E.I., et al., *The Middle East Respiratory Syndrome (MERS)*. *Infectious Disease Clinics*, 2019. 33(4): p. 891-905. DOI: <https://doi.org/10.18683/germs.2019.1155>
29. Organization, W.H., *Novel Coronavirus (2019-nCoV): situation report, 3*. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
30. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China*. *The Lancet*, 2020; 395(10223): p. 497-506. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
31. Zumla, A., et al., *Reducing mortality from 2019-nCoV: host-directed therapies should be an option*. *The Lancet*, 2020; 395(10224):e35-e36. DOI: [https://doi.org/10.1016/S0140-6736\(20\)30305-6](https://doi.org/10.1016/S0140-6736(20)30305-6)
32. Li, G., et al., *Coronavirus infections and immune responses*. *Journal of Medical Virology*, 2020. DOI: <https://doi.org/10.1002/jmv.25685>
33. Channappanavar, R. and S. Perlman. *Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology*. in *Seminars in immunopathology*. 2017. Springer. DOI: <https://doi.org/10.1007/s00281-017-0629-x>
34. Batawi, S., et al., *Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS)*. *Health and quality of life outcomes*, 2019. 17(1): p. 101. DOI: <https://doi.org/10.1186/s12955-019-1165-2>
35. Ngai, J.C., et al., *The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status*. *Respirology*, 2010. 15(3): p. 543-550. DOI: <https://doi.org/10.1111/j.1440-1843.2010.01720.x>
36. Zumla, A., et al., *Coronaviruses—drug discovery and therapeutic options*. *Nature reviews Drug discovery*, 2016. 15(5): p. 327. DOI: <https://doi.org/10.1038/nrd.2015.37>
37. Beigel, J.H., et al., *Advances in respiratory virus therapeutics—A meeting report from the 6th isrv Antiviral Group conference*. *Antiviral research*, 2019. DOI: <https://doi.org/10.1016/j.antiviral.2019.04.006>
38. Zumla, A., et al., *Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections*. 2015, Elsevier. DOI: <https://doi.org/10.1016/j.ijid.2015.09.005>
39. Gorbalenya, A.E., et al., *Nidovirales: Evolving the largest RNA virus genome*. *Virus Research*, 2006. 117(1): p. 17-37. DOI: <https://doi.org/10.1016/j.virusres.2006.01.017>
40. Nga, P.T., et al., *Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the largest RNA virus genomes*. *PLoS pathogens*, 2011. 7(9). DOI: <https://doi.org/10.1371/journal.ppat.1002215>
41. de Wit, E., et al., *SARS and MERS: recent insights into emerging coronaviruses*. *Nature Reviews Microbiology*, 2016. 14(8): p. 523-534. DOI: <https://doi.org/10.1038/nrmicro.2016.81>
42. Snijder, E.J., M. Kikkert, and Y. Fang, *Arterivirus molecular biology and pathogenesis*. *Journal of General Virology*, 2013. 94(10): p. 2141-2163. DOI: <https://doi.org/10.1099/vir.0.056341-0>
43. Gosert, R., et al., *RNA replication of mouse hepatitis virus takes place at double-membrane vesicles*. *Journal of virology*, 2002. 76(8): p. 3697-3708. DOI: <https://doi.org/10.1128/JVI.76.8.3697-3708.2002>
44. Hagemeyer, M.C., et al., *Visualizing coronavirus RNA synthesis in time by using click chemistry*. *Journal of virology*, 2012. 86(10): p. 5808-5816. DOI: <https://doi.org/10.1128/JVI.07207-11>



45. Pedersen, K.W., et al., *Open Reading Frame 1a-Encoded Subunits of the Arterivirus Replicase Induce Endoplasmic Reticulum-Derived Double-Membrane Vesicles Which Carry the Viral Replication Complex*. *Journal of Virology*, 1999. 73(3): p. 2016-2026. PMID: 9971782; PMCID: PMC104444
46. van Hemert, M.J., et al., *SARS-Coronavirus Replication/Transcription Complexes Are Membrane-Protected and Need a Host Factor for Activity In Vitro*. *PLOS Pathogens*, 2008. 4(5): p. e1000054. DOI: <https://doi.org/10.1371/journal.ppat.1000054>
47. Knoops, K., et al., *Ultrastructural characterization of arterivirus replication structures: reshaping the endoplasmic reticulum to accommodate viral RNA synthesis*. *Journal of Virology*, 2012. 86(5): p. 2474-2487. DOI: <https://doi.org/10.1128/JVI.06677-11>
48. Maier, H.J., et al., *Infectious bronchitis virus generates spherules from zippered endoplasmic reticulum membranes*. *MBio*, 2013. 4(5): p. e00801-13. DOI: <https://doi.org/10.1128/mBio.00801-13>
49. Ulasli, M., et al., *Qualitative and quantitative ultrastructural analysis of the membrane rearrangements induced by coronavirus*. *Cellular Microbiology*, 2010. 12(6): p. 844-861. DOI: [10.1111/j.1462-5822.2010.01437.x](https://doi.org/10.1111/j.1462-5822.2010.01437.x)
50. de Wilde, A.H., et al., *Host factors in coronavirus replication, in Roles of Host Gene and Non-coding RNA Expression in Virus Infection*. 2017, Springer. p. 1-42. DOI: [https://doi.org/10.1007/82\\_2017\\_25](https://doi.org/10.1007/82_2017_25)
51. van der Hoeven, B., et al., *Biogenesis and architecture of arterivirus replication organelles*. *Virus Research*, 2016. 220: p. 70-90. DOI: <https://doi.org/10.1016/j.virusres.2016.04.001>
52. Zhong, Y., Y.W. Tan, and D.X. Liu, *Recent Progress in Studies of Arterivirus- and Coronavirus-Host Interactions*. *Viruses*, 2012. 4(6): p. 980-1010. DOI: <https://doi.org/10.3390/v4060980>
53. Naoumov, N.V., *Cyclophilin inhibition as potential therapy for liver diseases*. *Journal of Hepatology*, 2014. 61(5): p. 1166-1174. DOI: <https://doi.org/10.1016/j.jhep.2014.07.008>
54. Nigro, P., G. Pompilio, and M.C. Capogrossi, *Cyclophilin A: a key player for human disease*. *Cell Death & Disease*, 2013. 4(10): p. e888-e888. DOI: <https://doi.org/10.1038/cddis.2013.410>
55. Hopkins, S. and P.A. Gallay, *The role of immunophilins in viral infection*. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 2015. 1850(10): p. 2103-2110. DOI: <https://doi.org/10.1016/j.bbagen.2014.11.011>
56. Carbajo-Lozoya, J., et al., *Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir*. *Virus Research*, 2014. 184: p. 44-53. DOI: <https://doi.org/10.1016/j.virusres.2014.02.010>
57. de Wilde, A.H., et al., *Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model*. *Virus Research*, 2017. 228: p. 7-13. DOI: <https://doi.org/10.1016/j.virusres.2016.11.011>
58. de Wilde, A.H., et al., *MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- $\alpha$  treatment*. *Journal of General Virology*, 2013. 94(8): p. 1749-1760. DOI: <https://doi.org/10.1099/vir.0.052910-0>
59. de Wilde, A.H., et al., *Cyclosporin A inhibits the replication of diverse coronaviruses*. *Journal of General Virology*, 2011. 92(11): p. 2542-2548. DOI: <https://doi.org/10.1099/vir.0.034983-0>
60. Kim, Y. and C. Lee, *Porcine epidemic diarrhea virus induces caspase-independent apoptosis through activation of mitochondrial apoptosis-inducing factor*. *Virology*, 2014. 460-461: p. 180-193. DOI: <https://doi.org/10.1016/j.virol.2014.04.040>
61. Tanaka, Y., et al., *Suppression of feline coronavirus replication in vitro by cyclosporin A*. *Veterinary Research*, 2012. 43(1): p. 41. DOI: <https://doi.org/10.1186/1297-9716-43-41>
62. von Brunn, A., *Editorial overview: Engineering for viral resistance*. *Current Opinion in Virology*, 2015. 14: p. v. DOI: <https://doi.org/10.1016/j.coviro.2015.08.009>
63. von Brunn, A., et al., *Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication*. *Current Opinion in Virology*, 2015. 14: p. 56-61. DOI: <https://doi.org/10.1016/j.coviro.2015.08.004>
64. Tanaka, Y., Y. Sato, and T. Sasaki, *Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B*. *Journal of General Virology*, 2017. 98(2): p. 190-200. DOI: <https://doi.org/10.1099/jgv.0.000663>
65. de Wilde, A.H., et al., *Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis*. *Journal of virology*, 2013. 87(3): p. 1454-1464. DOI: <https://doi.org/10.1128/JVI.02078-12>
66. Foss, D.V., M.L. Hochstrasser, and R.C. Wilson, *Clinical applications of CRISPR-based genome editing and diagnostics*. *Transfusion*, 2019. 59(4): p. 1389-1399. DOI: <https://doi.org/10.1111/trf.15126>
67. Brokowski, C. and M. Adli, *CRISPR ethics: moral considerations for applications of a powerful tool*. *Journal of molecular biology*, 2019. 431(1): p. 88-101. DOI: <https://doi.org/10.1016/j.jmb.2018.05.044>
68. Sugarman, J., *Ethics and germline gene editing*. *EMBO reports*, 2015. 16(8): p. 879-880. DOI: <https://doi.org/10.15252/embr.201540879>
69. Brokowski, C., *Do CRISPR germline ethics statements cut it?* *The CRISPR journal*, 2018. 1(2): p. 115-125. DOI: <https://doi.org/10.1089/crispr.2017.0024>